Valspodar

Generic Name: Valspodar

Drug Type: Small Molecule

Chemical Formula: C_₆₃H_₁₁₁N_₁₁O_₁₂

CAS Number: 121584-18-7

Unique Ingredient Identifier: Q7ZP55KF3X

Background: Valspodar has been used in trials studying the treatment of Cancer, Sarcoma, Leukemia, Lymphoma, and Breast Cancer, among others.

Clinical Trials

Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-09-03

Last Posted Date: 2010-01-06

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 70

Registration Number: NCT00002937

Locations: 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸
Beckman Research Institute, City of Hope, Duarte, California, United States
🇨🇦
Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada

and more 1 locations

Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: ara-C
Drug: Daunorubicin
Drug: Etoposide
Biological: Aldesleukin
Drug: PSC-833

First Posted Date: 2004-07-19

Last Posted Date: 2012-11-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 410

Registration Number: NCT00002925

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
State University of New York - Upstate Medical University, Syracuse, New York, United States

and more 30 locations

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-06-18

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 55

Registration Number: NCT00004217

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States

and more 87 locations

Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-05-12

Last Posted Date: 2023-06-07

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 36

Registration Number: NCT00002826

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Kimball Medical Center, Lakewood, New Jersey, United States
🇺🇸
St. Francis Medical Center, Trenton, New Jersey, United States

and more 6 locations

Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: etoposide
Drug: mitoxantrone hydrochloride
Drug: valspodar

First Posted Date: 2004-04-29

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00002912

Locations: 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Simmons Cancer Center - Dallas, Dallas, Texas, United States

and more 52 locations

Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers

Phase 1

Completed

Conditions: Sarcoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: pegylated liposomal doxorubicin hydrochloride
Drug: PSC 833

First Posted Date: 2004-02-16

Last Posted Date: 2013-04-12

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 14

Registration Number: NCT00003207

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)

Interventions: Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: etoposide
Drug: valspodar

First Posted Date: 2003-10-28

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 640

Registration Number: NCT00003190

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-07-09

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00002878

Locations: 🇺🇸
CCOP - Christiana Care Health Services, Wilmington, Delaware, United States
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada

and more 37 locations

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 3

Completed

Conditions: Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: Leukemia Research Fund

Target Recruit Count: 2000

Registration Number: NCT00005823

Locations: 🇬🇧
University Hospital of Wales, Cardiff, Wales, United Kingdom
🇬🇧
University College Hospital, London, England, United Kingdom
🇬🇧
Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Adult Acute Eosinophilic Leukemia
Adult Acute Erythroid Leukemia (M6)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Basophilic Leukemia
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)

Interventions: Drug: cytarabine
Biological: aldesleukin
Other: clinical observation
Drug: daunorubicin hydrochloride
Biological: filgrastim
Drug: etoposide
Other: pharmacological study
Drug: valspodar
Drug: busulfan
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 720

Registration Number: NCT00006363

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy